Mount Sinai’s Center for Alzheimer’s Disease

At Mount Sinai, the home of one of the world’s best and oldest centers dedicated to understanding and treating Alzheimer’s disease and other dementing illnesses, our scientists and clinicians are working hard at the bench and bedside to tackle one of today’s greatest challenges to our public health.

Research

Mount Sinai is carrying out state-of-the-art investigations in animal models and people with dementias to identify the causes of these illnesses and to use these discoveries to drive the search for new treatments and ultimately cures.

Our scientists are searching for the genes that make certain individuals particularly susceptible to dementias and have recently found several previously unknown genetic risk factors. Knowledge of risk genes enables the development of genetic mutant animals that harbor those genes and develop Alzheimer’s disease-like changes in their brain along with impaired cognition. Understanding how those genes lead to the illness provides novel insight into new ways of intervening, driving new approaches to treatment in the clinic.

Read more about research into Alzheimer’s disease and other dementias at our Centers of Excellence on Brain Aging, Neurodegeneration, Novel Neurotherapeutics and at Alzheimer's Disease Research Center.

Clinical Care

A major challenge in caring for people with Alzheimer’s disease and other dementias is first to diagnose the illness. Once diagnosed—while there are not yet definitive treatments—patients often benefit from a range of available medications, cognitive exercises and life training.

Mount Sinai’s Cognitive Health Center, a joint effort of the Departments of Neurology, Psychiatry, and Geriatrics and Palliative Care, offers consolidated diagnosis and treatment under one roof. Patients see neurologists, psychiatrists, neuropsychologists, and nursing care specialists who meet their medical and life care needs.

Mount Sinai’s Center for Alzheimer’s Disease: A History of Firsts

  • First use of cholinesterase inhibitors to improve cognition in humans
  • One of the nation’s first-funded, and still continuously funded, Alzheimer’s Disease Research Centers of the National Institutes of Health
  • Molecular cloning of amyloid precursor protein, a key pathogenic protein in Alzheimer’s disease
  • Visualization of degenerating nerve cells in living mice with Alzheimer’s disease genes

Contact Us

Lavina Wright-Woart
Patient Service Coordinator
Tel: 212-241-0783

Ways to Give